阿西美辛

  • 基本信息
  • 制备方法及用途
  • 物化性质
  • 安全信息
  • 毒理性
  • MSDS
  • 结构与计算化学
  • 上游产品

阿西美辛 基本信息

中文名称:
阿西美辛 
中文别名:
阿西美辛;
[1-(对氯苯甲酰基)-5-甲;
[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基吲哚-3-基]乙酰氧基乙酸;
1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-乙酸羧甲酯;
1-(对氯苯甲酰基)-5-甲氧基-2-甲基吲哚-3-乙酸羧甲酯;
1-(4-氯苯甲酰基)-5-甲氧基-2-甲基吲哚-3-乙酸羧甲基酯;
炎痛美新 
英文名称:
1H-Indole-3-aceticacid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester
英文别名:
acemetacin;
TVX-1322;
aximeixin;
BAY f4975;
Acemetacin;
acemix;
glycolic acid ester of indomethacin;
Emflex;
tv1322;
Solart;
rantudil;
[1-(4-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetoxyacetic Acid;
k-708;
1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid carboxymethyl ester;
rheumibis;
1-(4-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic Acid Carboxymethyl Ester 
CAS No.:
53164-05-9
分 子 式:

C21H18ClNO6

分 子 量:
415.83
精确分子量:
415.08200
PSA:
94.83000
MDL:
MFCD00151473
EINECS:
258-403-4
InChI:
InChI=1/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)
危险品标志:

VeryT+

风险术语:

R26/27/28;

安全术语:

R22;R25;R36/37/39;R45;

分子结构式:
SDS:
查看

阿西美辛 制备方法及用途

制备方法

方法1:以在吲哚美辛的合成中得到的N-(4-甲氧基苯基)-4-氯苯甲酰肼为原料,和(3-乙酰基丙酰氧基)乙酸苄酯(其制备见方法3)环合,得到[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-乙酰氧基]乙酸苄酯(I)。得到的苄酯(I)溶于冰醋酸中,在室温下在钯-炭催化剂上进行加氢,当氢吸收停止后,过滤去催化剂,滤液减压浓缩,残液加入石油醚中重结晶,得阿西美辛精品,熔点149.5~150.5℃,收率93%。 方法2:以吲哚美新为原料。 在搅拌下,将180g(0.503mo1)吲哚美新溶于900ml无水二甲基甲酰胺,加入35g(0.253mo1)磨细和干燥的碳酸钾,在50℃下搅拌45min。在15min中,滴入128g(0.56mo1)溴乙酸苄酯,在50℃下搅拌3h。过滤,滤液浓缩,剩余物溶于氯仿,用水洗至中性,无水硫酸钠干燥。浓缩,异丙醚-乙酸乙酯重结晶,得228g化合物(I),收率89.5%,熔点96℃。 60g(0.12mo1)化合物(I)溶于700ml乙酸乙酯,加入6g 5%钯-炭催化剂,在40℃下氢化1h,吸收约2.921L氢气(20℃)。过滤,浓缩,往剩余物加入石油醚(40~60℃),使结晶完全,并在冰箱中放置12h。过滤,先空气中干燥,后真空干燥,得46g阿西美辛,收率93%,熔点150~153℃。 方法3:以对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯为原料。(3-乙酰基丙酰氧基)乙酸苄酯的制备。93.5g(0.68mo1)干燥碳酸钾悬浮于650ml无水二甲基甲酰胺,加热至40℃,在70min内滴入116.1g(1.0mo1)3-乙酰基丙酸。加毕,冷至30℃,加入229.1g(1.0mo1)2-溴乙酸苄酯。在50℃下反应4h。过滤除去无机盐,用甲苯提取。提取液浓缩,剩余物溶于400ml二氯甲烷,水洗至中性,无水硫酸钠干燥。浓缩,剩余物溶于。1000ml异丙醚,加入冷至-25℃的1500ml石油醚(40~60℃),于-15℃下放置1h。过滤,在22℃下真空干燥,得235g(3-乙酰基丙酰氧基)乙酸苄酯,收率89%,熔点31.5~32.5℃,沸点176~178℃/1.20kPa。 26.3g(0.19mo1)对甲氧基苯肼溶于125ml冰乙酸和450ml水,在搅拌下,滴入50g(0.19mo1)(3-乙酰基丙酰氧基)乙酸苄酯,再搅拌1h。用甲苯提取,提取液水洗至中性,干燥,浓缩,得75.5g棕色油状的化合物(Ⅱ),直接用于下列反应。 将化合物(Ⅱ)直接溶于125ml无水吡啶,加入500ml无水乙醚,再在0℃加入43.5g对氯苯甲酰氯在250ml无水乙醚的溶液,在氮气保护下回流2h,冷却,水洗至中性,干燥,浓缩,得95g化合物(Ⅲ)的粗品。无需提纯,直接用于下步反应。 将化合物(Ⅲ)直接溶于380ml乙酸,在80℃下加热5min。减压浓缩,剩余物溶于氯仿,用碳酸氢钠溶液洗,并水洗至中性。用氧化铝层析,氯仿洗脱。浓缩后用乙醚重结晶,得10.6g化合物(I)。从对甲氧基苯肼计,收率11%。化合物(I)再如方法2还原为阿西美辛。 方法4:对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯也可先环合,再对氯苯甲酰化。 45.7g(0.26mo1)对甲氧基苯肼盐酸盐和69.2g(0.26mo1)(3-乙酰基丙酰氧基)乙酸苄酯溶于260ml乙酸,先在28℃搅拌42h,再在50℃搅拌5h。蒸出150~180ml溶剂后,加入500ml冰水,用4×100ml甲苯提取。提取液合并,用碳酸氢钾溶液洗至无酸,无水硫酸钠干燥。过滤,浓缩,得92g粗品。经蒸馏,可得76g化合物(IV),收率80%,沸点165℃(≤100Pa)。 77.5g(0.44mo1)对氯苯甲酰氯溶于275ml专用石油(沸点180~220℃)中加热至沸,在20min中,滴加41g(0.1lmo1)化合物(Ⅳ)。加毕,在190-195℃加热2~3h,至无氯化氢放出。冷至40℃,加入200ml乙醚。在室温下结晶后,再放入冰箱过夜。过滤收集结晶,用异丙醚洗,再用乙酸乙酯和异丙醚重结晶,得43.3g化合物(I),收率78%。化合物(I)再如方法2还原为阿西美辛。

合成制备方法

方法1:以在吲哚美辛的合成中得到的N-(4-甲氧基苯基)-4-氯苯甲酰肼为原料,和(3-乙酰基丙酰氧基)乙酸苄酯(其制备见方法3)环合,得到[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-乙酰氧基]乙酸苄酯(I)。得到的苄酯(I)溶于冰醋酸中,在室温下在钯-炭催化剂上进行加氢,当氢吸收停止后,过滤去催化剂,滤液减压浓缩,残液加入石油醚中重结晶,得阿西美辛精品,熔点149.5~150.5℃,收率93%。
                                                     方法2:以吲哚美新为原料。
        在搅拌下,将180g(0.503mo1)吲哚美新溶于900ml无水二甲基甲酰胺,加入35g(0.253mo1)磨细和干燥的碳酸钾,在50℃下搅拌45min。在15min中,滴入128g(0.56mo1)溴乙酸苄酯,在50℃下搅拌3h。过滤,滤液浓缩,剩余物溶于氯仿,用水洗至中性,无水硫酸钠干燥。浓缩,异丙醚-乙酸乙酯重结晶,得228g化合物(I),收率89.5%,熔点96℃。
60g(0.12mo1)化合物(I)溶于700ml乙酸乙酯,加入6g 5%钯-炭催化剂,在40℃下氢化1h,吸收约2.921L氢气(20℃)。过滤,浓缩,往剩余物加入石油醚(40~60℃),使结晶完全,并在冰箱中放置12h。过滤,先空气中干燥,后真空干燥,得46g阿西美辛,收率93%,熔点150~153℃。
方法3:以对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯为原料。(3-乙酰基丙酰氧基)乙酸苄酯的制备。93.5g(0.68mo1)干燥碳酸钾悬浮于650ml无水二甲基甲酰胺,加热至40℃,在70min内滴入116.1g(1.0mo1)3-乙酰基丙酸。加毕,冷至30℃,加入229.1g(1.0mo1)2-溴乙酸苄酯。在50℃下反应4h。过滤除去无机盐,用甲苯提取。提取液浓缩,剩余物溶于400ml二氯甲烷,水洗至中性,无水硫酸钠干燥。浓缩,剩余物溶于。1000ml异丙醚,加入冷至-25℃的1500ml石油醚(40~60℃),于-15℃下放置1h。过滤,在22℃下真空干燥,得235g(3-乙酰基丙酰氧基)乙酸苄酯,收率89%,熔点31.5~32.5℃,沸点176~178℃/1.20kPa。
        26.3g(0.19mo1)对甲氧基苯肼溶于125ml冰乙酸和450ml水,在搅拌下,滴入50g(0.19mo1)(3-乙酰基丙酰氧基)乙酸苄酯,再搅拌1h。用甲苯提取,提取液水洗至中性,干燥,浓缩,得75.5g棕色油状的化合物(Ⅱ),直接用于下列反应。
        将化合物(Ⅱ)直接溶于125ml无水吡啶,加入500ml无水乙醚,再在0℃加入43.5g对氯苯甲酰氯在250ml无水乙醚的溶液,在氮气保护下回流2h,冷却,水洗至中性,干燥,浓缩,得95g化合物(Ⅲ)的粗品。无需提纯,直接用于下步反应。
        将化合物(Ⅲ)直接溶于380ml乙酸,在80℃下加热5min。减压浓缩,剩余物溶于氯仿,用碳酸氢钠溶液洗,并水洗至中性。用氧化铝层析,氯仿洗脱。浓缩后用乙醚重结晶,得10.6g化合物(I)。从对甲氧基苯肼计,收率11%。化合物(I)再如方法2还原为阿西美辛。

                                                                   方法4:对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯也可先环合,再对氯苯甲酰化。
        45.7g(0.26mo1)对甲氧基苯肼盐酸盐和69.2g(0.26mo1)(3-乙酰基丙酰氧基)乙酸苄酯溶于260ml乙酸,先在28℃搅拌42h,再在50℃搅拌5h。蒸出150~180ml溶剂后,加入500ml冰水,用4×100ml甲苯提取。提取液合并,用碳酸氢钾溶液洗至无酸,无水硫酸钠干燥。过滤,浓缩,得92g粗品。经蒸馏,可得76g化合物(IV),收率80%,沸点165℃(≤100Pa)。
         77.5g(0.44mo1)对氯苯甲酰氯溶于275ml专用石油(沸点180~220℃)中加热至沸,在20min中,滴加41g(0.1lmo1)化合物(Ⅳ)。加毕,在190-195℃加热2~3h,至无氯化氢放出。冷至40℃,加入200ml乙醚。在室温下结晶后,再放入冰箱过夜。过滤收集结晶,用异丙醚洗,再用乙酸乙酯和异丙醚重结晶,得43.3g化合物(I),收率78%。化合物(I)再如方法2还原为阿西美辛。

用途简介

非甾体消炎镇痛药,有明显抑制炎症的作用。适用于风湿性关节炎、类风湿性关节炎、肌纤维组织炎、坐骨神经痛等的治疗。

用途

非甾体消炎镇痛药,有明显抑制炎症的作用。适用于风湿性关节炎、类风湿性关节炎、肌纤维组织炎、坐骨神经痛等的治疗。

阿西美辛 物化性质

外观与性状:
从石油醚得淡黄色细微结晶,熔点150-153℃。急性毒性LD50雄、雌小鼠,雄、雌大鼠(mg/kg):55.5,18.42,24.2,30.1口服;34.1,51.1,38.1,28.3静脉注射。
密度:
1.36g/cm3
熔点:
151.5°C
沸点:
565.5ºC at 760mmHg
闪点:
295.8°C
折射率:
1.611
其它信息:

1.性状:从石油醚得淡黄色细微结晶。

2.熔点:150-153℃。

阿西美辛 安全信息

包装等级:
II
风险类别:
6.1(a)
海关代码:
2942000000
危险类别码:
R26/27/28
安全说明:
S22-S25-S36/37/39-S45
危险标志:
T+:Verytoxic;

阿西美辛 毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NL3521400
CHEMICAL NAME :
1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester
CAS REGISTRY NUMBER :
53164-05-9
BEILSTEIN REFERENCE NO. :
0501672
LAST UPDATED :
199612
DATA ITEMS CITED :
24
MOLECULAR FORMULA :
C21-H18-Cl-N-O6
MOLECULAR WEIGHT :
415.85
WISWESSER LINE NOTATION :
T56 BNJ BVR& C1 D1VO1VQ GO1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
24200 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
23 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
28400 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
28300 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
19300 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
18420 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
23300 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
22800 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
34100 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
27600 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
64200 ug/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,657,1981
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
>600 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
300 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
194 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
192 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
280 mg/kg/35D-C
TOXIC EFFECTS :
Gastrointestinal - ulceration or bleeding from stomach Endocrine - other changes Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,665,1981 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
13500 ug/kg
SEX/DURATION :
female 17-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,777,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
56 mg/kg
SEX/DURATION :
female 16-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
44 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Newborn - behavioral
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,765,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
88 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - live birth index (measured after birth)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,765,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
108 mg/kg
SEX/DURATION :
female 17-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,777,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
351 mg/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
毒理学数据:

急性毒性LD50雄、雌小鼠,雄、雌大鼠(mg/kg):55.5,18.42,24.2,30.1口服;34.1,51.1,38.1,28.3静脉注射。

阿西美辛 MSDS


SECTION 1: Identification of the substance/mixture and of the company/undertaking
  Product identifiers
    Product name        : Acemetacin    
    REACH No.        : A registration number is not available for this substance as the substance    
    or its uses are exempted from registration, the annual tonnage does not
    require a registration or the registration is envisaged for a later
    registration deadline.
    CAS-No.        : 53164-05-9    
  Relevant identified uses of the substance or mixture and uses advised against
    Identified uses        : Laboratory chemicals, Manufacture of substances    
  
  

SECTION 2: Hazards identification
  Classification of the substance or mixture
  Classification according to Regulation (EC) No 1272/2008
    Acute toxicity, Inhalation (Category 1), H330
    Acute toxicity, Dermal (Category 2), H310
    Acute toxicity, Oral (Category 2), H300
    For the full text of the H-Statements mentioned in this Section, see Section 16.
  Classification according to EU Directives 67/548/EEC or 1999/45/EC
    T+ Very toxic        R26/27/28    
    For the full text of the R-phrases mentioned in this Section, see Section 16.
  Label elements
  Labelling according Regulation (EC) No 1272/2008
    Pictogram
    Signal word        Danger    
    Hazard statement(s)
    H300        Fatal if swallowed.    
    H310        Fatal in contact with skin.    
    H330        Fatal if inhaled.    
    Precautionary statement(s)
    P260        Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.    
    P264        Wash hands thoroughly after handling.    
    P280        Wear protective gloves/ protective clothing.    
    P284        Wear respiratory protection.    
    P302 + P350        IF ON SKIN: Gently wash with plenty of soap and water.    
    P310        Immediately call a POISON CENTER or doctor/ physician.    
    Supplemental Hazard        none    
    Statements
  Other hazards - none

SECTION 3: Composition/information on ingredients
  Substances
    Chemical characterization : Natural product
    Synonyms        : 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid    
    carboxymethyl ester
    Formula        : C21H18ClNO6    
    Molecular Weight        : 415,82 g/mol    
    CAS-No.        : 53164-05-9    
    EC-No.        : 258-403-4    
  Hazardous ingredients according to Regulation (EC) No 1272/2008
    Component        Classification        Concentration    
  Acemetacin
    CAS-No.        53164-05-9        Acute Tox. 1; Acute Tox. 2;        <= 100 %    
    EC-No.        258-403-4        H300, H310, H330    
  Hazardous ingredients according to Directive 1999/45/EC
    Component        Classification        Concentration    
  Acemetacin
    CAS-No.        53164-05-9        T+, R26/27/28        <= 100 %    
    EC-No.        258-403-4    
    For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
  Description of first aid measures
  General advice
    Consult a physician. Show this safety data sheet to the doctor in attendance.
  If inhaled
    If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
  In case of skin contact
    Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
  In case of eye contact
    Flush eyes with water as a precaution.
  If swallowed
    Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
  Most important symptoms and effects, both acute and delayed
    The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
    section 11
  Indication of any immediate medical attention and special treatment needed
    no data available

SECTION 5: Firefighting measures
  Extinguishing media
  Suitable extinguishing media
    Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
  Special hazards arising from the substance or mixture
    Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
  Advice for firefighters
    Wear self contained breathing apparatus for fire fighting if necessary.
  Further information
    no data available

SECTION 6: Accidental release measures
  Personal precautions, protective equipment and emergency procedures
    Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
    adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
    For personal protection see section 8.
  Environmental precautions
    Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
  Methods and materials for containment and cleaning up
    Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
    containers for disposal.
  Reference to other sections
    For disposal see section 13.

SECTION 7: Handling and storage
  Precautions for safe handling
    Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
    Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
    protection.
    For precautions see section 2.2.
  Conditions for safe storage, including any incompatibilities
    Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
  Specific end use(s)
    Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
  Control parameters
  Components with workplace control parameters
  Exposure controls
  Appropriate engineering controls
    Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
    the product.
  Personal protective equipment
  Eye/face protection
    Face shield and safety glasses Use equipment for eye protection tested and approved under
    appropriate government standards such as NIOSH (US) or EN 166(EU).
  Skin protection
    Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
    (without touching glove's outer surface) to avoid skin contact with this product. Dispose of
    contaminated gloves after use in accordance with applicable laws and good laboratory practices.
    Wash and dry hands.
    The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
    the standard EN 374 derived from it.
    Full contact
    Material: Nitrile rubber
    Minimum layer thickness: 0,11 mm
    Break through time: 480 min
    Material tested:Dermatril® (KCL 740 / Z677272, Size M)
    Splash contact
    Material: Nitrile rubber
    Minimum layer thickness: 0,11 mm
    Break through time: 480 min
    Material tested:Dermatril® (KCL 740 / Z677272, Size M)
    data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300,     test method: EN374
    If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
    contact the supplier of the CE approved gloves. This recommendation is advisory only and must
    be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
    anticipated use by our customers. It should not be construed as offering an approval for any
    specific use scenario.
  Body Protection
    Complete suit protecting against chemicals, The type of protective equipment must be selected
    according to the concentration and amount of the dangerous substance at the specific workplace.
  Respiratory protection
    Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
    respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
    controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
    respirators and components tested and approved under appropriate government standards such
    as NIOSH (US) or CEN (EU).
  Control of environmental exposure
    Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

SECTION 9: Physical and chemical properties
  Information on basic physical and chemical properties
    a) Appearance        Form: solid    
    b) Odour        no data available    
    c) Odour Threshold        no data available    
    d) pH        no data available    
    e) Melting point/freezing        no data available    
    point
    f) Initial boiling point and no data available
    boiling range
    g) Flash point        no data available    
    h) Evapouration rate        no data available    
    i) Flammability (solid, gas) no data available
    j) Upper/lower        no data available    
    flammability or
    explosive limits
    k) Vapour pressure        no data available    
    l) Vapour density        no data available    
    m) Relative density        no data available    
    n) Water solubility        no data available    
    o) Partition coefficient: n- no data available
    octanol/water
    p) Auto-ignition        no data available    
    temperature
    q) Decomposition        no data available    
    temperature
    r) Viscosity        no data available    
    s) Explosive properties        no data available    
    t) Oxidizing properties        no data available    
  Other safety information
    no data available

SECTION 10: Stability and reactivity
  Reactivity
    no data available
  Chemical stability
    Stable under recommended storage conditions.
  Possibility of hazardous reactions
    no data available
  Conditions to avoid
    no data available
  Incompatible materials
    no data available
  Hazardous decomposition products
    Other decomposition products - no data available
    In the event of fire: see section 5

SECTION 11: Toxicological information
  Information on toxicological effects
  Acute toxicity
    LD50 Oral - rat - 24,2 mg/kg
  Skin corrosion/irritation
    no data available
  Serious eye damage/eye irritation
    no data available
  Respiratory or skin sensitisation
    no data available
  Germ cell mutagenicity
    no data available
  Carcinogenicity
    IARC:        No component of this product present at levels greater than or equal to 0.1% is identified as    
    probable, possible or confirmed human carcinogen by IARC.
  Reproductive toxicity
    no data available
  Specific target organ toxicity - single exposure
    no data available
  Specific target organ toxicity - repeated exposure
    no data available
  Aspiration hazard
    no data available
  Additional Information
    RTECS: NL3521400
    To the best of our knowledge, the chemical, physical, and toxicological properties have not been
    thoroughly investigated.

SECTION 12: Ecological information
  Toxicity
    no data available
  Persistence and degradability
    no data available
  Bioaccumulative potential
    no data available
  Mobility in soil
    no data available
  Results of PBT and vPvB assessment
    PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
  Other adverse effects
    no data available

SECTION 13: Disposal considerations
  Waste treatment methods
  Product
    Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
    professional waste disposal service to dispose of this material. Dissolve or mix the material with a
    combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
  Contaminated packaging
    Dispose of as unused product.

SECTION 14: Transport information
  UN number
    ADR/RID: 2811        IMDG: 2811        IATA: 2811    
  UN proper shipping name
    ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (Acemetacin)
    IMDG: TOXIC SOLID, ORGANIC, N.O.S. (Acemetacin)
    IATA:        Toxic solid, organic, n.o.s. (Acemetacin)    
  Transport hazard class(es)
    ADR/RID: 6.1        IMDG: 6.1        IATA: 6.1    
  Packaging group
    ADR/RID: II        IMDG: II        IATA: II    
  Environmental hazards
    ADR/RID: no        IMDG Marine pollutant: no        IATA: no    
  Special precautions for user
    no data available

SECTION 15: Regulatory information
    This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
  Safety, health and environmental regulations/legislation specific for the substance or mixture
    no data available
  Chemical Safety Assessment
    For this product a chemical safety assessment was not carried out

SECTION 16: Other information
  Full text of H-Statements referred to under sections 2 and 3.
    Acute Tox.        Acute toxicity    
    H300        Fatal if swallowed.    
    H310        Fatal in contact with skin.    
    H330        Fatal if inhaled.    
  Full text of R-phrases referred to under sections 2 and 3
    T+        Very toxic    
    R26/27/28        Very toxic by inhalation, in contact with skin and if swallowed.    
  Further information
    Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
    only.
    The above information is believed to be correct but does not purport to be all inclusive and shall be
    used only as a guide. The information in this document is based on the present state of our knowledge
    and is applicable to the product with regard to appropriate safety precautions. It does not represent any
    guarantee of the properties of the product. Corporation and its Affiliates shall not be held
    liable for any damage resulting from handling or from contact with the above product. See
     and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

阿西美辛 分子结构与计算化学数据

分子结构数据

1、 摩尔折射率:106.05

2、 摩尔体积(cm3/mol):305.4

3、 等张比容(90.2K):809.7

4、 表面张力(dyne/cm):49.4

5、 极化率(10-24cm3):42.04

计算化学数据

1.疏水参数计算参考值(XlogP):无

2.氢键供体数量:1

3.氢键受体数量:6

4.可旋转化学键数量:7

5.互变异构体数量:无

6.拓扑分子极性表面积94.8

7.重原子数量:29

8.表面电荷:0

9.复杂度:620

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

推荐供应商更多供应商>>

上海吉至生化科技有限公司

产品介绍:
产品名称:2-(2-(1-(4-氯苯甲酰)-5-甲氧基-2-甲基-1H-吲哚-3-基)乙酰氧基)乙酸 Cas号:53164-05-9 纯度:≥98% 包装信息:1gea,5gea 价格:59.0元 - 135.0元
联系方式:
联系人:江珊 电话:021-57520831 手机:15316869680

湖北魏氏化学试剂股份有限公司

产品介绍:
产品名称:阿西美辛 Cas号:53164-05-9 纯度:99% 包装信息:17g 价格:洽谈
联系方式:
联系人:张经理 电话:027-59102966 手机:18717199209

郑州力本生物技术有限公司

产品介绍:
产品名称:阿西美辛 Cas号:53164-05-9 纯度:99 包装信息:25/桶kg 价格:洽谈
联系方式:
联系人:刘林 电话:0371-86536307 手机:13949119001

陕西萃康医药科技有限公司

产品介绍:
产品名称:阿西美辛 Cas号:53164-05-9 纯度: 包装信息:mg/瓶kg,1000/托kg,100/桶kg,10/袋g,25/桶kg 价格:洽谈
联系方式:
联系人:王 电话:13119157289 手机:13119157289

湖北鑫鸣泰化学有限公司

产品介绍:
产品名称:阿西美辛 Cas号:53164-05-9 纯度:99% 包装信息:100kg,200kg 价格:1.0元 - 1.0元
联系方式:
联系人:黄 电话:027-50662354 手机:13264726139

大华伟业医药化工有限公司

产品介绍:
产品名称:止血芳酸 Cas号:53164-05-9 纯度:98 包装信息:洽谈 价格:洽谈
联系方式:
联系人:宋先生 电话:02759212829 手机:15623424115

湖北江民泰华化工有限公司

产品介绍:
产品名称:阿西美辛 Cas号:53164-05-9 纯度:99% 包装信息:25kg,200kg 价格:洽谈
联系方式:
联系人:张经理 电话:13396038321 手机:13396038321

湖北恩星生物科技有限公司

产品介绍:
产品名称:阿西美辛 Cas号:53164-05-9 纯度: 包装信息:100kg,200kg,300kg,400kg,500kg 价格:64.0元 - 100.0元
联系方式:
联系人:邵经理 电话:16621771607 手机:16621771607

武汉鼎信通药业有限公司

产品介绍:
产品名称:阿西美辛 Cas号:53164-05-9 纯度: 包装信息:25/纸板桶kg 价格:洽谈
联系方式:
联系人:丁亮 电话:027-52344656 手机:15871722230

湖北魏氏化学试剂股份有限公司

产品介绍:
产品名称:阿西美辛 Cas号:53164-05-9 纯度: 包装信息:洽谈 价格:洽谈
联系方式:
联系人:刘涛 电话:027-59101766 手机:13125137661